Interim Positron Emission Tomography Response-Adapted Therapy in Advanced-Stage Hodgkin Lymphoma: Final Results of the Phase II Part of the HD0801 Study

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Pier Luigi ZinzaniAlessandro Levis

Abstract

The clinical impact of positron emission tomography (PET) evaluation performed early during first-line therapy in patients with advanced-stage Hodgkin lymphoma, in terms of providing a rationale to shift patients who respond poorly onto a more intensive regimen (PET response-adapted therapy), remains to be confirmed. The phase II part of the multicenter HD0801 study involved 519 patients with advanced-stage de novo Hodgkin lymphoma who received an initial treatment with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) and who underwent an early ifosfamide-containing salvage treatment followed by stem-cell transplantation if they showed a positive PET evaluation after two cycles of chemotherapy (PET2). The primary end point was 2-year progression-free survival calculated for both PET2-negative patients (who completed a full six cycles of ABVD treatment) and PET2-positive patients. Overall survival was a secondary end point. In all, 103 of the 512 evaluable patients were PET2 positive. Among them, 81 received the scheduled salvage regimen with transplantation, 15 remained on ABVD (physician's decision, mostly because of minimally positive PET2), five received an alternative treatment, and two were excluded because of d...Continue Reading

References

Sep 17, 2004·Cancer·Paolo G GobbiEdoardo Ascari
Jun 13, 2006·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P L ZinzaniM Baccarani
Jan 24, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonUNKNOWN International Harmonization Project on Lymphoma
Jan 24, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Malik E JuweidUNKNOWN Imaging Subcommittee of International Harmonization Project in Lymphoma
Jan 7, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Massimo FedericoUNKNOWN HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial
Mar 11, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Teruhiko TerasawaHirokazu Nagai
Jun 23, 2009·Leukemia & Lymphoma·Michel MeignanCorinne Haioun
Jul 18, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A AvigdorA Polliack
Aug 26, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andreas EngertMarkus Löffler
Dec 21, 2010·British Journal of Haematology·Andrea GallaminiUNKNOWN Gruppo Italiano Terapie Innovative nei Linfomi (GITIL)
Jul 22, 2011·The New England Journal of Medicine·Simonetta VivianiUNKNOWN Intergruppo Italiano Linfomi
Sep 7, 2011·European Journal of Nuclear Medicine and Molecular Imaging·Pier Luigi ZinzaniStefano Fanti
Oct 21, 2011·The New England Journal of Medicine·Peter BorchmannAndreas Engert
May 16, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·N MounierUNKNOWN Lymphoma Study Association (LYSA)

❮ Previous
Next ❯

Citations

Aug 17, 2016·European Journal of Haematology·Hugo J A Adams, Thomas C Kwee
Sep 14, 2016·Expert Review of Hematology·Pamela Blair Allen, Leo I Gordon
Oct 5, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M LadettoUNKNOWN ESMO Lymphoma Consensus Conference Panel Members
Jun 8, 2017·Hematological Oncology·Jack Broadfoot, Peter W M Johnson
Mar 4, 2018·Blood·Sean H Lim, Peter W M Johnson
May 24, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hugo J A Adams, Thomas C Kwee
May 24, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andrea GallaminiAlessandro Rambaldi
May 24, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Charles MesguichElif Hindié
Oct 11, 2017·Clinical Medicine Insights. Oncology·Pamela B Allen, Leo I Gordon
Jan 19, 2018·Acta Oncologica·Irina AmitaiAnat Gafter-Gvili
Feb 22, 2018·Acta Oncologica·Hugo J A Adams, Thomas C Kwee
Nov 9, 2018·British Journal of Haematology·Jemma Longley, Peter W M Johnson
Nov 9, 2018·British Journal of Haematology·Alessandro Broccoli, Pier Luigi Zinzani
Jan 14, 2018·Annals of Hematology·Hugo J A Adams, Thomas C Kwee
Oct 29, 2018·Annals of Hematology·Fang-Tian WuJian-Yong Li
Dec 7, 2018·Hematology·Michael A Spinner, Ranjana H Advani
Mar 29, 2019·Current Oncology Reports·Pamela B Allen, Jane N Winter
Jun 13, 2019·Hematological Oncology·Jemma Longley, Peter W M Johnson
Aug 1, 2019·British Journal of Haematology·Susan BalLuciano J Costa
Mar 21, 2020·Expert Review of Hematology·Melita Cirillo, Sven Borchmann
Jun 20, 2020·British Journal of Haematology·Peter HoklandJudith Trotman
Jul 29, 2016·Current Opinion in Oncology·Philippe Lewalle, Sebastian Wittnebel
Apr 16, 2017·European Journal of Nuclear Medicine and Molecular Imaging·Sally F Barrington, Regine Kluge
Jul 2, 2020·OncoTargets and Therapy·Shinichi MakitaKensei Tobinai
Aug 19, 2017·Drugs·Michael D Jain, John Kuruvilla
May 4, 2017·European Journal of Nuclear Medicine and Molecular Imaging·Elif HindiéNoël Milpied
Jul 15, 2017·European Journal of Nuclear Medicine and Molecular Imaging·Hugo J A Adams, Thomas C Kwee
Aug 1, 2019·Cancers·Theodoros P VassilakopoulosKostas Konstantopoulos
Jan 4, 2017·Journal of the National Cancer Institute·Catherine S DiefenbachNancy L Bartlett
Oct 25, 2016·Nuclear Medicine Communications·Hugo J A Adams, Thomas C Kwee
Mar 20, 2019·HemaSphere·Dennis A EichenauerAndreas Engert
Apr 26, 2019·Expert Opinion on Pharmacotherapy·David Gómez-AlmaguerAndrés Gómez-De León
Jun 17, 2020·Therapeutic Advances in Hematology·Noemie Lang, Michael Crump
Mar 14, 2019·British Journal of Haematology·Astrid PavlovskyUNKNOWN Grupo Argentino de tratamiento de Leucemia Aguda (GATLA), Argentina

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.